These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 19487371)

  • 1. Effective therapy for metastatic renal cancer, whither to now.
    Stadler WM
    J Clin Oncol; 2009 Aug; 27(22):3573-4. PubMed ID: 19487371
    [No Abstract]   [Full Text] [Related]  

  • 2. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hutson TE; Tomczak P; Michaelson MD; Bukowski RM; Oudard S; Negrier S; Szczylik C; Pili R; Bjarnason GA; Garcia-del-Muro X; Sosman JA; Solska E; Wilding G; Thompson JA; Kim ST; Chen I; Huang X; Figlin RA
    J Clin Oncol; 2009 Aug; 27(22):3584-90. PubMed ID: 19487381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sunitinib still fi rst-line therapy for metastatic renal cancer.
    Bagcchi S
    Lancet Oncol; 2014 Sep; 15(10):e420. PubMed ID: 25328943
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Bamias A
    Eur Urol; 2009 Jun; 55(6):1439. PubMed ID: 18950935
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
    Strumberg D
    J Clin Oncol; 2008 Jul; 26(20):3469-71; author reply 2471. PubMed ID: 18612169
    [No Abstract]   [Full Text] [Related]  

  • 6. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
    Johannsen M; Flörcken A; Bex A; Roigas J; Cosentino M; Ficarra V; Kloeters C; Rief M; Rogalla P; Miller K; Grünwald V
    Eur Urol; 2009 Jun; 55(6):1430-8. PubMed ID: 18950936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential sorafenib and sunitinib for renal cell carcinoma.
    Sablin MP; Negrier S; Ravaud A; Oudard S; Balleyguier C; Gautier J; Celier C; Medioni J; Escudier B
    J Urol; 2009 Jul; 182(1):29-34; discussion 34. PubMed ID: 19447417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for metastatic renal cell carcinoma: a review.
    Athar U; Gentile TC
    Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma.
    Thomas AA; Rini BI; Lane BR; Garcia J; Dreicer R; Klein EA; Novick AC; Campbell SC
    J Urol; 2009 Feb; 181(2):518-23; discussion 523. PubMed ID: 19100579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
    Fosså SD; Mickisch GH; De Mulder PH; Horenblas S; van Oosterom AT; van Poppel H; Fey M; Croles JJ; de Prijck L; Van Glabbeke M
    Cancer; 2004 Aug; 101(3):533-40. PubMed ID: 15274066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous daily dosing of sunitinib in patients with metastatic renal cell cancer.
    Harshman L; Srinivas S
    Onkologie; 2008 Sep; 31(8-9):432-3. PubMed ID: 18787349
    [No Abstract]   [Full Text] [Related]  

  • 12. Continuous therapy with sunitinib in patients with metastatic renal cell carcinoma.
    Kahl C; Hilgendorf I; Freund M; Casper J
    Onkologie; 2008 Sep; 31(8-9):485. PubMed ID: 18787358
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose interleukin-2 in metastatic renal cell carcinoma.
    Fernández-Rodríguez R; de Argumedo GL; Mañé JM; Muñoz A; Ferreiro J; Fuente N; López-Vivanco G
    J Clin Oncol; 2005 Sep; 23(27):6797-8; author reply 6798-9. PubMed ID: 16170190
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal clear-cell carcinoma of intermediate prognosis. Results and conclusions from a combined analysis.
    Bex A; Haanen JB; Vyth-Dreese FA; Horenblas S; de Gast GC
    Urol Int; 2008; 80(4):367-71. PubMed ID: 18587246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the role of novel agents in the treatment of renal cell carcinoma.
    Maluf FC; Fernandes Gdos S; Kann AG; Aguilar-Ponce JL; de la Garza J; Buzaid AC
    Cancer Treat Rev; 2008 Dec; 34(8):750-60. PubMed ID: 18801619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
    Gschwend JE
    Onkologie; 2010; 33 Suppl 1():10-1. PubMed ID: 20164670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
    Cella D; Li JZ; Cappelleri JC; Bushmakin A; Charbonneau C; Kim ST; Chen I; Motzer RJ
    J Clin Oncol; 2008 Aug; 26(22):3763-9. PubMed ID: 18669464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
    Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
    Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 51-year-old man with rapidly progressive metastatic sarcomatoid renal cell carcinoma: an apparent complete clinical response to second-line therapy with sunitinib and low-dose interferon-alpha.
    Bradshaw MJ; Cheville JC; Croghan GA
    Clin Adv Hematol Oncol; 2011 Jan; 9(1):61-4. PubMed ID: 21326149
    [No Abstract]   [Full Text] [Related]  

  • 20. [First-line therapy for German patients with metastatic kidney neoplasms in EORTC-Protocol 30012].
    Rexer H
    Urologe A; 2004 Aug; 43(8):992-3. PubMed ID: 15316609
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.